Product Information
URELLE TABLET is a brand product labeled by Viatris Specialty LLC, priced at $9.4315 per EA under NDC 00037632190. Its NADAC has been published 111 times since Aug 21, 2024.
URELLE TABLET
hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrateStrength
.12; 81; 10.8; 32.4; 40.8 mg/1; mg/1; mg/1; mg/1; mg/1
Manufacturer
Viatris Specialty LLCNDC
00037632190
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
1/1/2026
Active Ingredients
HYOSCYAMINE SULFATE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEApproval Type
Unapproved
On Market Since
1/12/2015
Pharmacological Classes
Price Statistics
The NADAC for URELLE TABLET has been published 111 times since Aug 21, 2024, and over the history we have for it it has risen 9.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.4315 per EA |
|---|---|
| All-time high | $9.4315 (Sep 30, 2026) |
| All-time low | $8.5749 (Dec 18, 2024) |
| 52-week high | $9.4315 |
| 52-week low | $8.9824 |
| Median price | $9.0036 |
| Average price | $9.0714 |
| Largest weekly change | +5.0% (Jan 7, 2026) |
| Weeks tracked | 111 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Viatris Specialty LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
hyoscyamine sulfate, methenamine, methylene blue, phenyl salicylate, and sodium phosphate, monobasic, monohydrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Oxidation-Reduction Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of URELLE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for URELLE TABLET, manufactured by Viatris Specialty LLC, is $9.4315 per EA (NDC 00037632190), effective Sep 30, 2026.
How has the price of URELLE TABLET changed over time?
Over the history we have for it, the NADAC for URELLE TABLET has risen 9.9%. It has been tracked across 111 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for URELLE TABLET?
Since Aug 21, 2024, the NADAC for URELLE TABLET has ranged from a low of $8.5749 (Dec 18, 2024) to a high of $9.4315 (Sep 30, 2026), with a median of $9.0036 per EA.
Are there cheaper alternatives to URELLE TABLET?
No other NADAC-published product currently shares the active ingredient and strength of URELLE TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures URELLE TABLET?
URELLE TABLET (NDC 00037632190) is labeled by Viatris Specialty LLC, and CMS classifies it as a brand product.